Tumor immunoediting and immunosculpting pathways to cancer progression

Reiman, Jennifer M.; Kmieciak, Maciej; Manjili, Masoud H.; Knutson, Keith L.

doi:10.1016/j.semcancer.2007.06.009

Cited by 171 publications

(140 citation statements)

References 149 publications

(166 reference statements)

Supporting

Mentioning

131

Contrasting

Unclassified

Order By: Relevance

“…To our knowledge, this is the first study to assess the significance of TILs as a marker for predicting the chemotherapeutic effectiveness in patients with stage IV CRC. Increasing evidence suggests that the balance between the immune cells of the host and the cancer cells plays an important role in tumor progression (21,22). The presence of TILs within the tumor microenvironment is considered to reflect the immune response of the host to the tumor (23).…”

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer

Shibutani

Maeda

Nagahara

et al. 2018

View full text Add to dashboard Cite

Abstract. Background Colorectal cancer (CRC) is one of the most common causes of cancer-related death worldwide (1). About 20-25% of patients with newly diagnosed CRC present with distant metastases (2-4), and only a small population of these patients can undergo curative operation (5). For patients with unresectable metastatic tumors, the standard treatment is systemic chemotherapy. As mentioned in the ESMO clinical practice guidelines (4), an individualized approach to clinical decision-making should be adopted according to the patient's stratification. Therefore, numerous attempts have been made to identify useful prognostic markers for accurate patient stratification.Anticancer immunity is known to affect cancer progression (6). Tumor-infiltrating lymphocytes (TILs), which reflect the immune status of the host (7), have been reported to correlate with the clinical outcome, including the chemotherapeutic outcome in patients with various types of cancer (8-10). However, the method of measuring TILs has differed among previous reports (11)(12)(13)(14)(15). Recently, a new method of measuring TILs in breast cancer was proposed by the International TILs Working Group, using H-E-stained sections (16). In the current study, we applied this method to CRC.The aim of the present study was to evaluate the significance of the TILs in the primary tumor as a marker for predicting the chemotherapeutic outcome in patients with stage IV CRC using the method proposed by the International TILs Working Group. Patients and MethodsPatients. We retrospectively reviewed a database of 57 patients who underwent palliative combination chemotherapy for unresectable metastatic colorectal cancer after resection of the primary tumor at

show abstract

Section: Discussionmentioning

confidence: 99%

Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer

Shibutani

Maeda

Nagahara

et al. 2018

View full text Add to dashboard Cite

show abstract

“…One of the reasons why cancer develops and spreads so rapidly is because of the weak immunosurveillance (Reiman et al, 2007). Proper function of cytotoxic T Lymphocytes (CTLs) is critical for immunosurveillance but cancer cells develop multiple mechanisms to evade the immune response.…”

Section: Introductionmentioning

confidence: 99%

Lack of any Association of the CTLA-4 +49 G/A Polymorphism with Breast Cancer Risk in a North Indian Population

Minhas¹,

Bhalla²,

Shokeen³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is an important protein involved in the regulation of the immune system. The +49 G/A polymorphism is the only genetic variation in the CTLA-4 gene that causes an amino acid change in the resulting protein. It is therefore the most extensively studied polymorphism among all CTLA-4 genetic variants and contributions to increasing the likelihood of developing cancer are well known in various populations, especially Asians. However, there have hiterto been no data with respect to the effect of this polymorphism on breast cancer susceptibility in our North Indian population. We therefore assayed genomic DNA of 250 breast cancer subjects and an equal number of age-, sex-and ethnicity-matched healthy controls for the CTLA-4 +49 G/A polymorphism but no significant differences in either the gene or allele frequency were found. Thus the CTLA-4 +49 G/A polymorphism may be associated with breast cancer in other Asians, but it appears to have no such effect in North Indians. The study also highlights the importance of conducting genetic association studies in different ethnic populations.

show abstract

“…An "immunosignature" is the pattern obtained when circulating antibodies in blood are allowed to bind to a large microarray of randomized-sequence peptides affixed to a solid surface (6). Cancers generate neoantigens by virtue of their mutagenic nature, and they tend to release native proteins and biomolecules not normally encountered by the immune system (7)(8)(9).…”

mentioning

confidence: 99%

“…Cancers generate neoantigens by virtue of their mutagenic nature, and they tend to release native proteins and biomolecules not normally encountered by the immune system (7)(8)(9). These behaviors can elicit an immune response (6,10,11). By virtue of the tremendous amplification afforded by B-cell replication (12), the signal elicited by the disease-specific antigens is massively amplified.…”

mentioning

confidence: 99%

Immunosignature system for diagnosis of cancer

Stafford

Cichacz

Woodbury

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Although the search for disease biomarkers continues, the clinical return has thus far been disappointing. The complexity of the body's response to disease makes it difficult to represent this response with only a few biomarkers, particularly when many are present at low levels. An alternative to the typical reductionist biomarker paradigm is an assay we call an "immunosignature." This approach leverages the response of antibodies to diseaserelated changes, as well as the inherent signal amplification associated with antigen-stimulated B-cell proliferation. To perform an immunosignature assay, the antibodies in diluted blood are incubated with a microarray of thousands of random sequence peptides. The pattern of binding to these peptides is the immunosignature. Because the peptide sequences are completely random, the assay is effectively disease-agnostic, potentially providing a comprehensive diagnostic on multiple diseases simultaneously. To explore the ability of an immunosignature to detect and identify multiple diseases simultaneously, 20 samples from each of five cancer cohorts collected from multiple sites and 20 noncancer samples (120 total) were used as a training set to develop a reference immunosignature. A blinded evaluation of 120 blinded samples covering the same diseases gave 95% classification accuracy. To investigate the breadth of the approach and test sensitivity to biological diversity further, immunosignatures of >1,500 historical samples comprising 14 different diseases were examined by training with 75% of the samples and testing the remaining 25%. The average accuracy was >98%. These results demonstrate the potential power of the immunosignature approach in the accurate, simultaneous classification of disease.cancer diagnostic | immunodiagnostic | antibody biomarker | peptide microarray

show abstract

Tumor immunoediting and immunosculpting pathways to cancer progression

Cited by 171 publications

References 149 publications

Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer

Tumor-infiltrating Lymphocytes Predict the Chemotherapeutic Outcomes in Patients with Stage IV Colorectal Cancer

Lack of any Association of the CTLA-4 +49 G/A Polymorphism with Breast Cancer Risk in a North Indian Population

Immunosignature system for diagnosis of cancer

Contact Info

Product

Resources

About